>> "... JPM ... nehmen ... im ersten Quartal 2018 25% der Allergan Aktien von Teva ab ..."
Ich suchte gerade mal eine Bestätigung für den Post von Steffen. Hier ein Auszug aus dem SC 13D Filing, falls es jemanden interessiert:
"Premium Forward Sale Allergan B1 (the “Counterparty”) and AWCH (the “Grantor”) entered into a Master Confirmation dated November 10, 2017 for Post-paid Premium Share Forward Transactions (the “Confirmation”), with JPMorgan Chase Bank, National Association, London Branch, as dealer (the “Dealer”), substantially in the form of Form of Master Confirmation: Post-paid Premium Share Forward Transactions filed herewith as Exhibit 4. Pursuant to a transaction under the Confirmation, (x) the Counterparty agreed to sell an aggregate of 25,000,000 Ordinary Shares, represented by ADSs, to Dealer at a price determined based on a premium over the average of the daily volume weighted average price of the ADSs over an agreed period, with Dealer having the right to set the length of the period within a minimum and maximum, and (y) the Counterparty and the Grantor granted a second lien to the Dealer on 100,291,067 Ordinary Shares, represented by ADSs, held by the Lender in order to secure the Counterparty’s obligations under the Confirmation. The transaction is expected to settle in the first quarter of 2018. From time to time, Allergan B1 and AWCH may enter into one or more similar transactions with the current or other dealers, each under a Master Confirmation for Post-paid Premium Share Forward Transactions, substantially in the form filed herewith as Exhibit 4, to sell their respective Ordinary Shares, represented by ADSs." |